Radiation Therapy for Metastatic Prostate Cancer
Metastasis-Directed Radiation Therapy
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding metastasis-directed radiation therapy (MDRT) to standard hormone therapy improves overall survival in patients with metastatic prostate cancer.
Study Overview
The study, published in the Journal of Clinical Oncology, involved 327 patients with hormone-sensitive metastatic prostate cancer. Patients were randomly assigned to receive either standard hormone therapy alone or hormone therapy plus MDRT. MDRT was delivered to all known metastatic lesions.
Results
The study found that the addition of MDRT to hormone therapy significantly improved overall survival. The median overall survival was 5.2 years in the MDRT group compared to 3.6 years in the hormone therapy alone group.
MDRT also improved progression-free survival, which is the time until the cancer progresses or the patient dies. The median progression-free survival was 2.1 years in the MDRT group compared to 1.4 years in the hormone therapy alone group.
Conclusion
The study shows that the combination of MDRT and hormone therapy is an effective treatment for metastatic prostate cancer. This combination can improve overall survival and progression-free survival.
0 Comments